TrialChest2022

Reboxetine Plus Oxybutynin for OSA Treatment: A 1-Week, Randomized, Placebo-Controlled, Double-Blind Crossover Trial.

Elisa Perger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.